Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent BioSolutions	$6.47 -0.5%	$5.28	$4.02 ▼ $15.10	$350.91M	2.09	1.85 million shs	708,459 shs
MYGN Myriad Genetics	$4.16 -3.9%	$6.80	$3.81 ▼ $29.30	$383.46M	2.01	1.16 million shs	1.66 million shs
RIGL Rigel Pharmaceuticals	$19.53 +1.8%	$18.36	$7.48 ▼ $29.82	$349.04M	1.34	217,502 shs	122,628 shs
SNSS Sunesis Pharmaceuticals		$3.53	$1.12 ▼ $11.30	$96.26M	2.27	4.33 million shs	1.20 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent BioSolutions	+2.78%	+0.87%	+19.41%	-8.07%	+37.63%
MYGN Myriad Genetics	+4.34%	+6.39%	-42.27%	-60.89%	-81.43%
RIGL Rigel Pharmaceuticals	-2.19%	-8.36%	-1.13%	-11.89%	+106.03%
SNSS Sunesis Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EBS Emergent BioSolutions	4.3129 of 5 stars	3.5	1.0	0.0	4.6	3.4	2.5	1.3
MYGN Myriad Genetics	3.7741 of 5 stars	4.0	1.0	0.0	4.1	1.1	1.7	0.6
RIGL Rigel Pharmaceuticals	2.6845 of 5 stars	3.2	1.0	0.0	0.0	3.3	1.7	1.9
SNSS Sunesis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EBS Emergent BioSolutions	3.00	Buy	$14.33	121.71% Upside
MYGN Myriad Genetics	2.06	Hold	$14.79	255.43% Upside
RIGL Rigel Pharmaceuticals	2.40	Hold	$36.40	86.38% Upside
SNSS Sunesis Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SNSS, MYGN, RIGL, and EBS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	MYGN Myriad Genetics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$20.00 ➝ $6.00
5/15/2025	MYGN Myriad Genetics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.50 ➝ $9.00
5/8/2025	MYGN Myriad Genetics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
5/7/2025	MYGN Myriad Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$18.00
5/7/2025	MYGN Myriad Genetics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $8.00
5/7/2025	MYGN Myriad Genetics	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$19.00 ➝ $10.00
5/7/2025	MYGN Myriad Genetics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $7.00
5/7/2025	MYGN Myriad Genetics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$22.00 ➝ $6.00
5/7/2025	RIGL Rigel Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $23.00
4/17/2025	MYGN Myriad Genetics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00
4/9/2025	MYGN Myriad Genetics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EBS Emergent BioSolutions	$930.30M	0.38	$0.72 per share	8.92	$12.51 per share	0.52
MYGN Myriad Genetics	$831.30M	0.46	N/A	N/A	$9.53 per share	0.44
RIGL Rigel Pharmaceuticals	$203.08M	1.72	N/A	N/A	($1.64) per share	-11.91
SNSS Sunesis Pharmaceuticals	$2.07M	0.00	N/A	N/A	$1.42 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EBS Emergent BioSolutions	-$760.50M	-$2.71	N/A	3.12	N/A	-18.55%	-9.91%	-3.31%	8/5/2025 (Estimated)
MYGN Myriad Genetics	-$263.30M	-$1.12	N/A	N/A	N/A	-14.09%	-4.51%	-3.07%	8/5/2025 (Estimated)
RIGL Rigel Pharmaceuticals	-$25.09M	$2.07	139.51	18.60	N/A	2.46%	-14.80%	3.03%	8/5/2025 (Estimated)
SNSS Sunesis Pharmaceuticals	-$23.33M	-$2.70	N/A	N/A	N/A	N/A	-179.05%	-72.27%	N/A

Latest SNSS, MYGN, RIGL, and EBS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	EBS Emergent BioSolutions	$0.49	$0.71	+$0.22	$1.19	$218.50 million	$222.20 million
5/6/2025	Q1 2025	MYGN Myriad Genetics	-$0.05	-$0.03	+$0.02	N/A	$200.37 million	$195.90 million
5/6/2025	Q1 2025	RIGL Rigel Pharmaceuticals	$0.14	$0.63	+$0.49	$0.63	$43.87 million	$53.33 million
3/4/2025	Q4 2024	RIGL Rigel Pharmaceuticals	$0.30	$0.80	+$0.50	$0.80	$57.59 million	$57.60 million
3/3/2025	Q4 2024	EBS Emergent BioSolutions	-$0.35	$0.05	+$0.40	-$0.58	$254.67 million	$194.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EBS Emergent BioSolutions	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SNSS Sunesis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EBS Emergent BioSolutions	1.30	2.88	1.47
MYGN Myriad Genetics	0.05	1.90	1.73
RIGL Rigel Pharmaceuticals	N/A	1.96	1.87
SNSS Sunesis Pharmaceuticals	N/A	7.74	7.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EBS Emergent BioSolutions	78.40%
MYGN Myriad Genetics	99.02%
RIGL Rigel Pharmaceuticals	66.23%
SNSS Sunesis Pharmaceuticals	28.41%

Insider Ownership

Company	Insider Ownership
EBS Emergent BioSolutions	1.20%
MYGN Myriad Genetics	2.40%
RIGL Rigel Pharmaceuticals	9.48%
SNSS Sunesis Pharmaceuticals	4.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EBS Emergent BioSolutions	2,420	54.28 million	53.53 million	Optionable
MYGN Myriad Genetics	2,600	92.18 million	89.12 million	Optionable
RIGL Rigel Pharmaceuticals	160	17.87 million	16.02 million	Optionable
SNSS Sunesis Pharmaceuticals	24	18.09 million	N/A	Optionable

SNSS, MYGN, RIGL, and EBS Headlines

Recent News About These Companies

GE Profile PTD7000SNSS Wall Oven

October 28, 2024 | consumerreports.org

Peter J Barris's Net Worth

September 1, 2024 | benzinga.com

GE JTD3000SNSS Wall Oven

August 13, 2024 | consumerreports.org

AQSZF Aequus Pharmaceuticals Inc.

December 20, 2023 | seekingalpha.com

4 Breakout Stocks to Watch Going Into Labor Day

August 6, 2022 | thestreet.com

4 Stocks Under $10 to Trade Now

January 14, 2022 | thestreet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNSS, MYGN, RIGL, and EBS Company Descriptions

Emergent BioSolutions NYSE:EBS

$6.46 -0.04 (-0.54%)

Closing price 03:59 PM Eastern

Extended Trading

$6.42 -0.05 (-0.77%)

As of 04:33 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Myriad Genetics NASDAQ:MYGN

$4.16 -0.17 (-3.93%)

Closing price 04:00 PM Eastern

Extended Trading

$4.35 +0.19 (+4.54%)

As of 04:16 PM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Rigel Pharmaceuticals NASDAQ:RIGL

$19.53 +0.34 (+1.77%)

Closing price 04:00 PM Eastern

Extended Trading

$19.74 +0.22 (+1.10%)

As of 04:43 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Sunesis Pharmaceuticals NASDAQ:SNSS

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time